These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 32938950)
21. LRIG1 engages ligand VISTA and impairs tumor-specific CD8 Ta HM; Roy D; Zhang K; Alban T; Juric I; Dong J; Parthasarathy PB; Patnaik S; Delaney E; Gilmour C; Zakeri A; Shukla N; Rupani A; Phoon YP; Liu C; Avril S; Gastman B; Chan T; Wang LL Sci Immunol; 2024 May; 9(95):eadi7418. PubMed ID: 38758807 [TBL] [Abstract][Full Text] [Related]
22. VISTA is an immune checkpoint molecule for human T cells. Lines JL; Pantazi E; Mak J; Sempere LF; Wang L; O'Connell S; Ceeraz S; Suriawinata AA; Yan S; Ernstoff MS; Noelle R Cancer Res; 2014 Apr; 74(7):1924-32. PubMed ID: 24691993 [TBL] [Abstract][Full Text] [Related]
23. Discovery and Optimization of Small-Molecule Ligands for V-Domain Ig Suppressor of T-Cell Activation (VISTA). Gabr MT; Gambhir SS J Am Chem Soc; 2020 Sep; 142(38):16194-16198. PubMed ID: 32894020 [TBL] [Abstract][Full Text] [Related]
24. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity. Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806 [TBL] [Abstract][Full Text] [Related]
25. VISTA: Coming of age as a multi-lineage immune checkpoint. ElTanbouly MA; Schaafsma E; Noelle RJ; Lines JL Clin Exp Immunol; 2020 May; 200(2):120-130. PubMed ID: 31930484 [TBL] [Abstract][Full Text] [Related]
26. Identification of active small-molecule modulators targeting the novel immune checkpoint VISTA. Li TT; Jiang JW; Qie CX; Xuan CX; Hu XL; Liu WM; Chen WT; Liu J BMC Immunol; 2021 Aug; 22(1):55. PubMed ID: 34380434 [TBL] [Abstract][Full Text] [Related]
27. VISTA Regulates the Development of Protective Antitumor Immunity. Le Mercier I; Chen W; Lines JL; Day M; Li J; Sergent P; Noelle RJ; Wang L Cancer Res; 2014 Apr; 74(7):1933-44. PubMed ID: 24691994 [TBL] [Abstract][Full Text] [Related]
28. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma. Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845 [TBL] [Abstract][Full Text] [Related]
29. VISTA: A Target to Manage the Innate Cytokine Storm. ElTanbouly MA; Zhao Y; Schaafsma E; Burns CM; Mabaera R; Cheng C; Noelle RJ Front Immunol; 2020; 11():595950. PubMed ID: 33643285 [TBL] [Abstract][Full Text] [Related]
30. Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression. Xu W; Dong J; Zheng Y; Zhou J; Yuan Y; Ta HM; Miller HE; Olson M; Rajasekaran K; Ernstoff MS; Wang D; Malarkannan S; Wang L Cancer Immunol Res; 2019 Sep; 7(9):1497-1510. PubMed ID: 31340983 [TBL] [Abstract][Full Text] [Related]
31. The immune checkpoint molecule VISTA regulates allergen-specific Th2-mediated immune responses. Ohno T; Zhang C; Kondo Y; Kang S; Furusawa E; Tsuchiya K; Miyazaki Y; Azuma M Int Immunol; 2018 Feb; 30(1):3-11. PubMed ID: 29267882 [TBL] [Abstract][Full Text] [Related]
32. VISTA.COMP - an engineered checkpoint receptor agonist that potently suppresses T cell-mediated immune responses. Prodeus A; Abdul-Wahid A; Sparkes A; Fischer NW; Cydzik M; Chiang N; Alwash M; Ferzoco A; Vacaresse N; Julius M; Gorczysnki RM; Gariépy J JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931757 [TBL] [Abstract][Full Text] [Related]
33. The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers. Wang G; Tai R; Wu Y; Yang S; Wang J; Yu X; Lei L; Shan Z; Li N Cytokine Growth Factor Rev; 2020 Apr; 52():1-14. PubMed ID: 32057701 [TBL] [Abstract][Full Text] [Related]
34. The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead. Hosseinkhani N; Derakhshani A; Shadbad MA; Argentiero A; Racanelli V; Kazemi T; Mokhtarzadeh A; Brunetti O; Silvestris N; Baradaran B Front Immunol; 2021; 12():676181. PubMed ID: 34093577 [TBL] [Abstract][Full Text] [Related]
35. VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy. Huang X; Zhang X; Li E; Zhang G; Wang X; Tang T; Bai X; Liang T J Hematol Oncol; 2020 Jun; 13(1):83. PubMed ID: 32600443 [TBL] [Abstract][Full Text] [Related]
36. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer. Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J Front Immunol; 2020; 11():563044. PubMed ID: 33250890 [TBL] [Abstract][Full Text] [Related]
38. Design, Synthesis, and Antitumor Activity Evaluation of Novel VISTA Small Molecule Inhibitors. Sun C; He Y; Wang G; Zhang G; Zhang Y; Shen H; Hu L; Sun Y; Jiang B; Wang X; Yuan K; Min W; Wang L; Sun H; Xiao Y; Yang P J Med Chem; 2024 Mar; 67(5):3590-3605. PubMed ID: 38412237 [TBL] [Abstract][Full Text] [Related]
39. Enhancement of Radiation Therapy through Blockade of the Immune Checkpoint, V-domain Ig Suppressor of T Cell Activation (VISTA), in Melanoma and Adenocarcinoma Murine Models. Duval KEA; Tavakkoli AD; Kheirollah A; Soderholm HE; Demidenko E; Lines JL; Croteau W; Zhang SC; Wagner RJ; Aulwes E; Noelle RJ; Hoopes PJ Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762046 [TBL] [Abstract][Full Text] [Related]
40. VISTA expressed in tumour cells regulates T cell function. Mulati K; Hamanishi J; Matsumura N; Chamoto K; Mise N; Abiko K; Baba T; Yamaguchi K; Horikawa N; Murakami R; Taki M; Budiman K; Zeng X; Hosoe Y; Azuma M; Konishi I; Mandai M Br J Cancer; 2019 Jan; 120(1):115-127. PubMed ID: 30382166 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]